MYCN and medulloblastoma: Increase of MYCN expression has been reported in cancer with an aggressive course and poor prognosis, particularly that of neural origin, and also in neuroendocrine tumors [30] including medulloblastoma [36], while there is not much evidence linking MYCN to glial-derived tumors [37].